Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival

Marietta Nygaard1 · Niels Smedegaard Andersen1 · Claus Ernst Moser2 · Gitte Olesen1 · Ida Marie Schjødt1 · Carsten Heilmann1 · Henrik Sengeløv1

Received: 13 September 2017 / Revised: 19 December 2017 / Accepted: 31 December 2017 / Published online: 1 February 2018
© Macmillan Publishers Limited, part of Springer Nature 2018

Abstract
Several immunosuppressive drugs have been proposed for second-line treatment of steroid-refractory acute graft versus host disease (aGvHD) after allogeneic hematopoietic stem cell transplantation. However, the studies on these drugs are small, retrospective, uncontrolled and use different endpoints. Therefore, it remains unknown which treatment is superior. We retrospectively evaluated 68 consecutive patients treated with infliximab for aGvHD. We adhered to recently proposed guidelines for aGvHD trials and thus evaluated response on day 7 and 28. Furthermore, we assessed the composite endpoint 6 months freedom from treatment failure (6MFTF). The majority of patients had grade III-IV aGvHD. We found that 41 patients (60%) responded on day 7 and 31 patients (46%) on day 28. Twenty-four patients (35%) achieved 6MFTF. The main reasons for failure within 6 months were death (n = 31) or additional immunosuppression (n = 16). By six and 24 months, 44 and 34% of the patients were alive respectively. Patients with response to infliximab on day 7 and 28 had significantly higher overall survival (OS) probability than non-responders. We show that response on day 7 and 28 identifies high and low risk groups. Patients who fail to respond should be identified early and offered alternative therapy.

Introduction
Acute Graft versus Host Disease (aGvHD) is a common and severe complication to hematopoietic stem cell transplantation (HSCT). There is consensus that first-line treatment is 1–2 mg/kg glucocorticoid; however for steroid-refractory patients, it remains unknown which treatment option is superior [1].

Several second-line therapies have been proposed; most of which add further immunosuppression and thus increase risk of infection and relapse. Most studies show some effect of the studied second-line agent, but the prognosis remains poor with only approximately 50% of patients surviving 6 months [1].

Comparison of studies is complicated by the small number of studied patients, lack of control groups, inconsistent treatment schedules and different criteria for response assessment [2]. Recent guidelines for response assessment in aGvHD studies recommend evaluating treatment response at fixed timepoints [3, 4]. Furthermore, a composite endpoint, 6 months freedom from treatment failure (6MFTF), is increasingly used [5, 6].

In our center, we have used the tumor necrosis factor α (TNF-α) inhibitor infliximab as second-or further-line treatment for aGvHD since the year 2000. TNF-α is significantly increased in patients with aGVHD [7], and inhibition of TNF-α may potentially control aGVHD [8]. Inhibition of TNF-α has been suggested in all phases of aGvHD treatment; as prevention [9, 10], as part of primary aGvHD treatment [11–15], and most commonly as treatment for steroid-refractory or steroid-dependent aGVHD [16–25].

In this retrospective evaluation, we adhere to the recently proposed guidelines for response assessment. We intend to supplement earlier evidence of the effect of infliximab as
second-line-treatment and to validate if response on day 7 and 28 after second-or-further line treatment is predictive of survival as proposed in above referred guidelines. To our knowledge, this is the largest study on patients with mainly severe steroid-resistant aGvHD treated with infliximab. Hopefully this will further elucidate the role of infliximab in the treatment of aGvHD.

Patients and methods

A single investigator (MN) reviewed the records of all patients treated with infliximab between 01-01-2000 and 17-06-2014. All patients gave informed consent for use of data and the study was conducted according to the directions of the regional Ethics Committee. Myeloablative conditioning regimens were total body irradiation (TBI) 12 Gy with cyclophosphamide 120 mg/kg or etoposide phosphate 1800 mg/m² or busulphane 12.8 mg/kg plus cyclophosphamide 120 mg/kg. Non-myeloablative regimens were TBI 200 cGy (or in a few cases 300 or 400 cGy) combined with fludarabine 90 mg/m² or fludarabine 90 mg/m² without TBI. Graft versus host disease prophylaxis was cyclosporine A (CsA) with short-course methotrexate in myeloablative HSCT and tacrolimus (TAC) or CsA and mycophenolate mofetil (MMF) in non-myeloablative HSCT. Donors were 10/10 or 9/10 human leucocyte antigen (HLA) identical siblings or HLA-matched unrelated donors; except for two with single antigen mismatch.

Acute GVHD diagnosis

Both classical aGvHD, occurring within 100 days after HSCT, and persistent or late-onset aGvHD were included. Gastro-intestinal GvHD was diagnosed by histological examination of a sigmoideum biopsy. Skin GVHD was diagnosed by presence of a typical maculopapular rash. Liver GVHD was diagnosed by increase in serum bilirubin without other possible causes. Grading of aGvHD was assessed by standard criteria [26].

Insufficient response to standard high-dose (1–2 mg/kg) glucocorticoid treatment was defined as aggressive progression of de novo aGvHD grade within 3 days, no response after 1 week of therapy or inability to taper glucocorticoid dose after an initial response. If glucocorticoids had been tapered below 0.5 mg/kg before reoccurrence of aGvHD, the day of increased glucocorticoid dose was considered the start of the current aGvHD episode.

Response assessment

Baseline for aGvHD grading score was the day infliximab was started. Overall response of aGvHD was assessed on day 7 and 28 after start of infliximab treatment. Complete response (CR) was defined as resolution of all indicators of aGvHD, very good partial response (VGPR) was an approximation of CR as described by Martin et al. [4]. Partial response (PR) was improvement of one or more grades in any affected organ without progression or de novo aGvHD in other organs. If progression was noted in any organ or additional treatment was administered, patients were classified as having progressive disease (PD). Change in immunosuppression due to side effects was not considered PD. Both substitution and addition of immunosuppression were at the discretion of the treating physician. Stable disease (SD) was unaltered grading in all affected organs.

On day 7, any response (CR, VGPR or PR) was considered significant treatment effect. On day 28 only CR and VGPR were considered significant treatment effect. We also evaluated 6MFTF where failure was defined as death, relapse of malignancy or need for additional systemic immunosuppression within 6 months [5, 6].

Treatment with infliximab

Infliximab was used off label for steroid-refractory or steroid-dependent aGvHD as allowed by the national health authorities. No patient was excluded from start of infliximab treatment due to poor performance status, infection or financial issues. Standard dosage of infliximab was 10 mg/kg once weekly, but if the patient had PD, an intensified schedule with two doses weekly could be used. Unless severe infections or PD occurred, infliximab was continued until the patient had CR/VGPR.

Infections

All patients received posaconazole or liposomal Amphotericin B, acyclovir or valaciclovir, and co-trimoxazole or dapsone. If neutrophil count was below 0.5 × 10⁹/L, cefazidine or meropenem was administered. When body temperature exceeded 38 °C, blood, urine and sputum cultures were taken followed by preemptive antibiotic administration. Quantitative PCR analysis for CMV in blood was performed weekly, and if positive, valganciclovir, ganciclovir or foscarnet replaced acyclovir/valaciclovir. Verified bacterial, fungal or viral infections were recorded for 6 months after start of infliximab. Occurrence of severe or life threatening/fatal infections was registered according to BMT CTN Data Coordinating center’s definition of infection severity (https://web.emmes.com/study/bmt2/public/Definition/Definitions_of_Inf_Severity.pdf).

Statistics

Association of baseline variables to day 7 and 28 response and 6MFTF was analyzed using the χ² test or Fishers exact
test for categorical variables and Mann–Whitney’s test for continuous variables. Overall survival (OS) probability was estimated by the Kaplan–Meier method with comparison done by the log rank test. Survival probability was estimated with start of infliximab therapy as day 0. When using day 7 and day 28 as landmarks for impact on survival, only patients alive at that time point were included in the analysis. Statistical tests were two-tailed and a \( p \)-value < 0.05 was considered statistically significant. The SPSS\textsuperscript{©} software version 22 was used for all statistical analysis.

### Results

Between 01-01-2000 and 17-06-2014, a total of 938 patients received an allogeneic HSCT at our center and of these, 315 (35.8%) developed grade II-IV aGvHD. Sixty-eight patients (7.2%) received in infliximab as second-or further-line treatment of aGvHD. Patient and treatment characteristics of these patients are shown in Table 1. Three patients developed aGvHD after donor lymphocyte infusion, six patients after a second transplant.

### Treatment of aGvHD

At initial diagnosis of aGvHD, 66 patients received 2 mg/kg methylprednisolone (MP) or prednisolone. Two patients started on lower doses but were increased to 2 mg/kg due to progression in aGvHD. When infliximab treatment was initiated, nine patients received less than 1 mg/kg glucocorticoid due to uncontrolled diabetes \((n = 2)\), active CMV infection \((n = 1)\) or tapering of prolonged steroid treatment \((n = 6)\). Tapering of glucocorticoids had been attempted in 32 (47%) patients before aGvHD progression necessitated increase to 2 mg/kg again and thereafter infliximab.

At start of infliximab treatment, concomitant immunosuppressive medication was: CsA \((n = 21)\), TAC \((n = 11)\), TAC + MMF \((n = 17)\), CsA + MMF \((n = 15)\), MMF \((n = 3)\), and MMF plus sirolimus \((n = 1)\). Four patients received other aGvHD therapies prior to or at the same time.

### Table 1

| Characteristics                          | \( N \) | %   |
|-----------------------------------------|--------|-----|
| Age, mean (range)                       | 50.2   | (25–73) |
| Sex                                     |        |     |
| Male                                    | 44     | 65  |
| Female                                  | 24     | 35  |
| Diagnosis                               |        |     |
| Acute myeloid leukemia                  | 18     | 26  |
| MDS                                     | 16     | 24  |
| Acute lymphoid leukemia                 | 8      | 12  |
| Chronic lymphocytic leukemia            | 8      | 12  |
| Chronic myeloid leukemia                | 4      | 6   |
| Hodgkins lymphoma                       | 3      | 4   |
| Non-Hodgkins lymphoma                   | 6      | 9   |
| Multiple myeloma                        | 3      | 4   |
| Severe aplastic anemia                  | 1      | 1   |
| Prolymphocyte leukemia                  | 1      | 1   |
| Remission status at HCT                 |        |     |
| In remission                            | 47     | 69  |
| Not in remission                        | 21     | 31  |
| Conditioning                            |        |     |
| Myeloablative                           | 22     | 32  |
| Non-myeloablative                       | 46     | 68  |
| Donorrelation                           |        |     |
| Related                                 | 34     | 50  |
| Unrelated                               | 34     | 50  |
| Cell source                             |        |     |
| Peripheral blood                        | 54     | 79  |
| Bone marrow                             | 14     | 21  |
| Recipient/donor sex                     |        |     |
| Female/male                             | 11     | 20  |
| Female/female                           | 9      | 16  |
| Male/female                             | 9      | 16  |
| Male/male                               | 26     | 47  |
| GVHD profylaxis (at time of aGVHD diagnosis) |    |     |
| CsA                                     | 21     | 31  |
| TCR                                     | 11     | 16  |
| CsA + MMF                               | 15     | 22  |
| TCR + MMF                               | 17     | 25  |
| MMF                                     | 4      | 6   |
| Overall GVHD grade                      |        |     |
| Grade II                                | 17     | 25  |
| Grade III                               | 33     | 49  |
| Grade IV                                | 18     | 26  |
| Organ involvement of aGVHD              |        |     |
| Gastrointestinal only                   | 30     | 44  |
| Gastrointestinal + liver                | 11     | 16  |
| Gastrointestinal + skin                 | 10     | 15  |
| Gastrointestinal + liver + skin         | 1      | 2   |

### Table 1 (continued)

| Characteristics                          | \( N \) | %   |
|-----------------------------------------|--------|-----|
| Skin only                               | 15     | 22  |
| Liver only                              | 1      | 2   |
| Days from HCT/DLI to aGVHD onset        | 48     | (14–337) |
| Days from steroid to infliximab         | 6      | (1–125) |
| Number of infliximab doses at day 28    | 3      | (1–9) |
| Total number of infliximab doses        | 4      | (1–13) |
as starting infliximab; antithymocyte globulin (ATG) 
(\(n = 2\)), extracorporeal photopheresis (\(n = 1\)) or 
ultraviolet phototherapy (UVA1) (\(n = 1\)).

Median of three infliximab doses (range 1–9) was 
administered within 28 days. Schedules for 
administration of infliximab were: standard weekly 
(\(n = 24\)), twice weekly (\(n = 31\)), twice weekly 
for a total of two doses (\(n = 7\)) or 
only one dose (\(n = 6\)). Infliximab was stopped 
before day 28 (\(n = 53\)) for the following 
reasons: improvement in aGvHD (\(n = 29\)), infection 
(\(n = 6\)), progression with need 
for additional treatment (\(n = 8\)) and death (\(n = 10\)).

Additional therapy before day 28 was MMF (\(n = 4\)), 
MMF + 1 g MP (\(n = 1\)), daclizumab + ATG (\(n = 1\)), 
rituximab (\(n = 1\)) or sirolimus (\(n = 1\)). Additions after 
day 28 were UVA1 (\(n = 3\)), MMF (\(n = 2\)), sirolimus (\(n = 1\)), 
daclizumab (\(n = 1\)), 1 g MP + sirolimus (\(n = 1\)). Eleven 
patients continued infliximab after addition of therapy, 
whereas infliximab had stopped prior to addition in five 
patients. Eight patients changed immunosuppression due to 
side effects, usually thrombotic microangiopathy or 
impaired kidney function.

Glucocorticoid dose was reduced by 50% in 45 patients 
after a median of 3 weeks (range 1–8). At 24 weeks, 30 
evaluable patients received no glucocorticoid (\(n = 13\)), \(\leq 10\) 
mg daily (\(n = 9\)), and >10 mg daily (\(n = 8\)). Overall, glu-
corticoids were discontinued in 18 patients with 13 of 
those eventually free from all immunosuppressive 
medication.

Response

On day 7, CR, VGPR or PR was obtained in 41 patients 
(60%), and on day 28, CR or VGPR was obtained in 31 
(46%) patients. When including PR in the day 28 response, 
we found a response rate of 66%. Twenty-four patients 
(35%) achieved 6MFTF, where the majority had CR/VGPR 
on day 28 (\(n = 20, 83\%\)). Reasons for treatment failure 
within 6 months were death (\(n = 31\)) or additional immu-
nosuppression (\(n = 16\)). See flow chart in Fig. 1. Of the 
seven patients with additional treatment before day 28, one 
had CR on day 28, five had PD and two had died.

The only variable significantly predictive of responses on 
day 7, day 28 and 6MFTF was grade of aGvHD at start of 
infliximab treatment (day 7 \(p = 0.001\), day 28 \(p = 0.005\) 
and 6MFTF \(p = 0.002\)). Analysis of other possible baseline 
predictors of response is shown in supplemental Table 1. 
For patients with gastrointestinal involvement, there was a 
significantly positive association with CR/VGPR on day 28 
(\(p = 0.014\)), but not with other endpoints.

Survival

At six and 24 months, 44 and 34% of the patients were 
avlive, respectively. The median observation time was
116 months (range 30.5–205). Patients with response on 
day 7 and 28 had significantly higher OS probability than 
non-responders with an OS rate after two years of 49 and 
58%, respectively. Overall survival and OS according to

![Flowchart of the course of the patients according to response on day 28](image-url)
response are shown in Fig. 2. Patients with no more than PR on day 28 had OS comparable to patients with PD on day 28 (data not shown). In univariate analysis, higher grade of aGvHD, unrelated donor, and no response on day 7 and 28 were associated with poor survival. See supplemental Table 2. Causes of death are shown in Table 2.

| Causes of death                               | N  (%) |
|-----------------------------------------------|--------|
| Organ failure caused by GVHD                  | 20 (38.5) |
| Infections                                    | 17 (32.7) |
| Invasive fungal (N = 8)                       |        |
| Viral (N = 4)                                 |        |
| Bacterial (N = 3)                             |        |
| Unspecified (N = 2)                           |        |
| Relapse                                       | 5 (9.6) |
| Multi-organ-failure                           | 4 (7.7) |
| Other                                         | 6 (11.5) |
| Cerebral hemorrhage (N = 3)                   |        |
| Cancer pharynx (N = 1)                        |        |
| Myocardial infarction (N = 1)                 |        |
| Hepatic failure of unknown cause (N = 1)      |        |

Chronic GVHD

Chronic GVHD occurred in 22 of the 34 patients who survived at least 3 months. Only four of the 16 patients still alive at the time of analysis were free from cGvHD. Median time to diagnosis of cGvHD from administration of infliximab was 30 weeks (range 16–108).

Discussion

In this study, we show that infliximab has effect in steroid-refractory or steroid-dependent aGvHD as it has also been shown previously. Patriarca et al. [20] reported on 32 patients with mainly severe aGvHD and found 19% of patients had CR and 40% PR on day 7. Couriel et al. [21] evaluated 21 patients with primarily grade II steroid-refractory aGvHD and found response in 67% on day 7. These day 7 responses are comparable to our day 7 CR/VGPR/PR rate of 60% in patients with mainly severe aGvHD.

Pidala et al. [23] reported that only 15% of the patients treated with infliximab achieved CR at median 6 days (range 2–26). They concluded that infliximab may be of limited value in grade III-IV aGvHD. This is contradicted by our findings where the majority of patients also have severe aGvHD. The reasons for the poor results reported by Pidala et al. are not clear, but may be due to less intensive treatment or early response assessment. The PR rates are not stated in the study.

As shown by Martin et al. [1] results on second-line treatments are variable, but with most agents demonstrating some activity. Overall CR/PR rate for 29 studies was 58% but this should be interpreted with caution because the timing and definition of response varies, and furthermore there are differences in patient populations. Of the included studies, five reported response on day 28 with CR
proportions between 0.08–0.42 and only two reported response on day 7 with CR/PR proportions of 0.83 and 0.67.

None of the suggested therapies have proved superior to others. Therefore, we adhered to the recently proposed guidelines for response assessment in aGVHD [4, 27] to facilitate comparison both within studies on infliximab but also with other therapeutic options in the absence of large randomized, controlled studies.

Patients treated with second-line therapy for aGvHD have dismal prognoses with a 6 month survival estimate of 0.49 [1]. We confirm this finding with high early mortality with only 44% of the patients alive after 6 months.

Response assessment on day 7 and 28 has primarily been tested in first-line aGvHD treatment where especially response on day 28 is shown to correlate strongly with long-term endpoints including survival [27–29]. For second-line treatment, it is important to have an early predictor of treatment success such as response on day 7. With this study, we validate that both having CR, VGPR or PR on day 7 and having either CR or VGPR on day 28 are predictive of survival. We hypothesized that having only PR by day 28 after second-line therapy indicates insufficient treatment effect. This was confirmed as patients with PR on day 28 had OS comparable to patients with PD on day 28. Early identification of patients with a dismal prognosis is

### Table 3 Overview of the microbiological agents found in the patients during treatment with infliximab

| Blood                        | Sputum/BAL*fluid | Feces/intestine | Urine |
|------------------------------|------------------|-----------------|-------|
| **Gram-negative**            |                  |                 |       |
| Escherichia coli             | 8                | 5              |       |
| Pseudomonas aeruginosa       | 4                | 3              |       |
| Klebsiella pneumoniae        | 3                | 1              |       |
| Listeria monocytogenes       | 2                | 1              |       |
| Gram-positive                |                  |                 |       |
| Enterococcus faecalis        | 6                | 3              |       |
| Streptococcus pneumoniae     | 2                | 1              |       |
| Micrococcus luteus           | 1                | 1              |       |
| Staphylococcus epidermidis   | 7                | 4              |       |
| Staphylococcus aureus        | 2                | 2              |       |
| Staphylococcus haemolyticus  | 1                | 3              |       |
| Kogulase-negative coccus     | 1                | 1              |       |
| Non-hemolytic streptococcus  | 1                | 1              |       |
| Yeast                        |                  |                 |       |
| Candida albicans             | 2                | 2              |       |
| Candida parapsilosis         | 1                | 2              |       |
| Candida glabrata             | 3                | 2              |       |
| Virus                        |                  |                 |       |
| Cytomegalovirus              | 17               | 11             |       |
| Epstein Barr virus           | 2                | 2              |       |
| Influenza A                  | 2                |                |       |
| Respiratory syncytial virus  | 2                |                |       |
| Parainfluenza                | 2                |                |       |
| Cytomegalovirus              | 1                |                |       |
| Corona virus                 | 1                |                |       |
| Boca virus                   | 1                |                |       |
| Metapneumovirus              | 1                |                |       |
| CNS                          |                  |                 |       |
| Gram-negative                |                  |                 |       |
| Listeria monocytogenes       | 1                | 1              |       |
| Moulds                       |                  |                 |       |
| Aspergillus fumigatus        | 1                | 1              |       |
| Virus                        |                  |                 |       |
| Cytomegalovirus              | 1                | 1              |       |

*BAL broncho-alveolar lavage
important in aGvHD, because alternative therapy should be initiated as soon as possible.

We found low incidence of relapse, but infections were a substantial problem with 78% of patients having severe and/or fatal infections despite prophylactic antimicrobial medication. Marty et al. [30] previously reported increased incidence of non-Candida invasive fungal infections in patients treated with infliximab for aGvHD, which is in line with our observation of invasive Aspergillus infections. Carcica-Cadenas et al. [31] found 1-year incidence or bacterial, viral and fungal infections to be respectively 74, 65 and 14% after second-line treatment of aGvHD with anti-cytokine therapy. Whether patients treated with infliximab have additional, different, or more severe infections compared to other treatments, cannot be concluded from these data. Careful monitoring of the patients, including relevant sampling and clinical microbiological diagnosis as well as early, aggressive antibiotic treatment, is pivotal.

The results from the present study are limited by the retrospective nature, the heterogeneity of patients and their aGvHD-treatment. Before infliximab was initiated, the patients had been affected by aGvHD for variable periods of time and were on variable systemic immunosuppression. Both steroid-refractory and steroid-dependent patients were treated with infliximab and it is possible that treatment schedules and/or duration should be different for these different groups. The optimal treatment schedule for infliximab remains unknown.

Additional immunosuppression was administered to one fourth of the patients, and this could potentially account for responses or influence survival. However, it was the most severely affected patients who received additional therapy and we found that having additional therapy was associated with worse response on day 28 (seven of eight had PD or had died).

**Conclusion**

We validate, in the presently largest study on infliximab, that response on day 7 and 28 is able to identify high and low risk groups after second-or-further-line treatment. In patients with CR or VGPR on day 28, 58% were alive after two years, which is encouraging considering the majority of patients had grade III-IV aGvHD. Our results are in line with previously published reports on infliximab and other second-line therapies. Further research, preferably prospective and controlled with comparable endpoints, is warranted. Patients who fail to respond should be identified early and offered alternative therapies.

**Acknowledgements** Supported by unrestricted grants from the Novo Nordisk Foundation (NNF15OC0014158) and the Danish Cancer Society.

**Compliance with ethical standards**

**Conflict of interest:** The authors declare that they have no conflict of interest.

**References**

1. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2012;18:1150–63.
2. Martin PJ, Inamoto Y, Flowers MED, Carpenter PA. Secondary treatment of acute graft-versus-host disease: a critical review. Biol Blood Marrow Transpl. 2012;18:982–8.
3. Martin PJ. Study design and endpoints in graft-versus-host disease. Best Pract Res Clin Haematol. 2008;21:357–72.
4. Martin PJ, Bachier CR, Klingemann H-G, McCarthy PL, Szabolcs P, Uberti JP, et al. Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. Biol Blood Marrow Transpl. 2009;15:777–84.
5. Sengsayadeth S, Savani BN, Jagasia M, Goodman S, Greer JP, Chen H, et al. Six-month freedom from treatment failure is an important end point for acute GVHD clinical trials. Bone Marrow Transpl. 2014;49:236–40.
6. Inamoto Y, Martin PJ, Storer BE, Mielcarek M, Storb RF, Carpenter PA. Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease. Haematologica. 2014;99:385–91.
7. Remmerber M, Ringden O, Markling L. TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transpl. 1995;15:99–104.
8. Korngold R, Marin JC, De Baca ME, Murphy GF, Giles-komar J. Role of tumor necrosis factor alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transpl. 2003;303:292–303.
9. Choi SW, Stiff P, Cooke K, Ferrara JLM, Braun T, Kitko C, et al. TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes. Biol Blood Marrow Transpl. 2012;18:1525–32.
10. Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, et al. Addition of Infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. Biol Blood Marrow Transpl. 2008;14:783–9.
11. Alousi AM, Weisdorf DJ, Logan BR, Bolan J, Carter S, DiFronzo N, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009;114:511–7.
12. Uberti JP, Ayash L, Ratanatharathorn V, Silver S, Reynolds C, Becker M, et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:680–7.
13. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. 2008;111:2470–5.
14. Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B, Khouri I, et al. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transpl. 2009;15:1555–62.
15. Gatza E, Braun T, Levine JE, Ferrara JLM, Zhao S, Wang T, et al. Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2014;20:1426–34.

16. Herve BP, Flesch M, Tiberghien P, Wijdenes J, Racadot E, Bordigoni P, et al. Phase I-II Trial a Monoclon Anti-Tumor Necrosis Factor. Blood. 1992;79:3362–8.

17. Kobbe G, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M, et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transpl. 2001;28:47–9.

18. Rivkina AM, Stump LS. Infl iximab in graft-versus-host disease. Am J Health Syst Pharm. 2002;59:1271–5.

19. Yamane T, Yamamura R, Aoyama Y, Nakamae H, Hasegawa T, Sakamoto C, et al. Infl iximab for the treatment of severe steroid refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation. Leuk Lymphoma. 2003;44:2095–7.

20. Patriarca F, Sperotto A, Damiani D, Morreale G, Bonifazi F, Olivieri A, et al. Infl iximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica. 2004;89:1352–9.

21. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004;104:649–54.

22. Sleight BS, Chan KW, Braun TM, Serrano A, Gilman A L. Infl iximab for GVHD therapy in children. Bone Marrow Transpl. 2007;40:473–80.

23. Pidala J, Kim J, Field T, McBride A, Kharfan-Dabaja M, Perkins J, et al. Infl iximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transpl. 2009;15:1116–21.

24. Rao K, Rao A, Karlsson H, Jagani M, Veys P, Amrolia PJ. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease. J Pediatr Hematol Oncol. 2009;31:456–61.

25. Yang J, Cheuk DKL, Ha SY, Chiang AKS, Lee TL, Ho MHK, et al. Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation. Pediatr Transpl. 2012;16:771–8.

26. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.

27. MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood. 2010;115:5412–7.

28. Saliba RM, Couriel DR, Giralt S, Rondon G, Okoroji G-J, Rashid A, et al. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transpl. 2012;47:125–31.

29. Levine JE, Logan B, Wu J, Alousi AM, Ho V, Bolaños-Meade J, et al. Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transpl. 2010;16:1693–9.

30. Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH, et al. Infl iximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood. 2003;102:2768–76.

31. Garcia-Cadenas I, Rivera I, Martino R, Esquirol A, Barba P, Novelli S, et al. Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. Bone Marrow Transpl. 2017;52:107–13.